GTC
RAPT

Ghost Tree Capital’s RAPT Therapeutics RAPT Stock Holding History

Ghost Tree Capital’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-37,500
Closed -$915K – 71
2024
Q2 		$915K Hold
37,500
– – 0.29% 53
2024
Q1 		$2.69M Buy
+37,500
New +$5.21M 0.75% 44

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ghost Tree Capital's RAPT Position: Q1 2023 in Review

Ghost Tree Capital sold out of RAPT Therapeutics (RAPT) in Q1 2023, closing a stake of 15,625 shares — an estimated $2.48M sold.

Ghost Tree Capital first reported a position in RAPT in Q3 2020 and held it in 8 quarters. The position peaked at $18.1M in Q2 2021. 106 funds tracked by Wall St. Rank hold RAPT as of Q1 2023.

  • Ghost Tree Capital reported no remaining RAPT Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 15,625 RAPT Therapeutics shares in Q1 2023, an estimated $2.48M.
  • Ghost Tree Capital first reported a position in RAPT Therapeutics in Q3 2020 and held it in 8 quarters.
  • Ghost Tree Capital's RAPT Therapeutics position peaked at $18.1M in Q2 2021.
  • 106 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2023.

Based on Ghost Tree Capital's 13F filing for Q1 2023, filed 15 May 2023.